SONN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 09:38):

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action...

Stats
Today's Volume	431.00
Average Volume	104 046
Market Cap	5.52M
EPS	$0 ( 2024-02-14 )
Next earnings date	( $0.130 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.17
ATR14	$0.0180 (1.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-27	Rao Raghu	Buy	31 250	Warrant to Purchase Common Stock
2023-10-27	Rao Raghu	Buy	15 625	Common Stock
2023-10-27	Mohan Pankaj	Buy	68 750	Warrant to Purchase Common Stock
2023-10-27	Mohan Pankaj	Buy	34 375	Common Stock
2023-08-07	Markey John	Sell	0	Common Stock

INSIDER POWER
82.29
Last 88 transactions
Buy: 5 035 351 \| Sell: 2 861 714

Sonnet Biotherapeutics Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sonnet Biotherapeutics Financials

Annual	2023
Revenue:	$147 805
Gross Profit:	$72 055.00 (48.75 %)
EPS:	$-18.14

Q1	2024
Revenue:	$18 626.00
Gross Profit:	$-1 348.00 (-7.24 %)
EPS:	$-0.310

Q4	2023
Revenue:	$37 255.00
Gross Profit:	$17 789.00 (47.75 %)
EPS:	$-2.10

Q3	2023
Revenue:	$36 850.00
Gross Profit:	$17 873.00 (48.50 %)
EPS:	$-2.96

Financial Reports:

No articles found.

Sonnet Biotherapeutics

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.